Kiniksa Pharmaceuticals International Plc stock is traded at $88.34, with a volume of 961,739. It is down -8.09% in the last 24 hours and up +15.76% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Previous Close:
$96.12
Open:
$95.49
24h Volume:
961,739
Relative Volume:
0.76
Market Cap:
$6.94B
Revenue:
$754.05M
Net Income/Loss:
$73.06M
P/E Ratio:
97.37
EPS:
$0.9073
Net Cash Flow:
$164.23M
1W Performance:
-9.45%
1M Performance:
+15.76%
6M Performance:
+55.69%
1Y Performance:
+125.70%
1-Day Range:
$87.30$96.99
1-Week Range:
$87.30$96.99
52-Week Range:
$37.02$98.48
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International PlcSector
HealthcarePhone
(781) 431-9100Address
105 PICCADILLY, SECOND FLOOR, LONDON, United KingdomMarket Cap
Revenue
Net Income
Cash Flow
EPS